Scoop: Mer­ck scraps PhII tri­als of Alzheimer’s and de­pres­sion small mol­e­cule af­ter liv­er tox­i­c­i­ty ob­ser­va­tions

Mer­ck has end­ed work on two sep­a­rate Phase II stud­ies of its small mol­e­cule for treat­ment-re­sis­tant de­pres­sion and mild-to-mod­er­ate Alzheimer’s dis­ease, the phar­ma con­firmed to End­points News.

An un­blind­ed re­view of da­ta from the two tri­als “sug­gest­ed MK-1942 was po­ten­tial­ly as­so­ci­at­ed with ob­ser­va­tions of liv­er tox­i­c­i­ty,” a Mer­ck spokesper­son told End­points in an email Wednes­day morn­ing. “This re­view was trig­gered by the iden­ti­fi­ca­tion of ab­nor­mal­i­ties in liv­er func­tion tests for sev­er­al study par­tic­i­pants. No re­lat­ed Se­ri­ous Ad­verse Events (SAE) were re­port­ed.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER